K S Alzimami1, A K Ma. 1. Department of Radiological Sciences, King Saud University, Riyadh, Saudi Arabia. kalzimami@ksu.edu.sa
Abstract
OBJECTIVE: Positron emission tomography (PET) using zirconium-89 ((89)Zr) is complicated by its complex decay scheme. In this study, we quantified the effective dose from (89)Zr and compared it with fluorine-18 fludeoxyglucose ((18)F-FDG). METHODS: Effective dose distribution in a PET/CT facility in Riyadh was calculated by Monte Carlo simulations using MCNPX. The positron bremsstrahlung, the annihilation photons, the delayed gammas from (89)Zr and those emissions from (18)F-FDG were modelled in the simulations but low-energy characteristic X-rays were ignored. RESULTS: On the basis of injected activity, the dose from (89)Zr was higher than that of (18)F-FDG. However, the dose per scan from (89)Zr became less than that from (18)F-FDG near the patient, owing to the difference in injected activities. In the corridor and control rooms, the (89)Zr dose was much higher than (18)F-FDG, owing to the difference in attenuation by the shielding materials. CONCLUSION: The presence of the high-energy photons from (89)Zr-labelled immuno-PET radiopharmaceuticals causes a significantly higher effective dose than (18)F-FDG to the staff outside the patient room. Conversely, despite the low administered activity of (89)Zr, it gives rise to a comparable or even lower dose than (18)F-FDG to the staff near the patient. This interesting result raises apparently contradictory implications in the radiation protection considerations of a PET/CT facility. ADVANCES IN KNOWLEDGE: To the best of our knowledge, radiation exposure to staff and public in the PET/CT unit using (89)Zr has not been investigated. The ultimate output of this study will lead to the optimal design of the facility for routine use of (89)Zr.
OBJECTIVE: Positron emission tomography (PET) using zirconium-89 ((89)Zr) is complicated by its complex decay scheme. In this study, we quantified the effective dose from (89)Zr and compared it with fluorine-18 fludeoxyglucose ((18)F-FDG). METHODS: Effective dose distribution in a PET/CT facility in Riyadh was calculated by Monte Carlo simulations using MCNPX. The positron bremsstrahlung, the annihilation photons, the delayed gammas from (89)Zr and those emissions from (18)F-FDG were modelled in the simulations but low-energy characteristic X-rays were ignored. RESULTS: On the basis of injected activity, the dose from (89)Zr was higher than that of (18)F-FDG. However, the dose per scan from (89)Zr became less than that from (18)F-FDG near the patient, owing to the difference in injected activities. In the corridor and control rooms, the (89)Zr dose was much higher than (18)F-FDG, owing to the difference in attenuation by the shielding materials. CONCLUSION: The presence of the high-energy photons from (89)Zr-labelled immuno-PET radiopharmaceuticals causes a significantly higher effective dose than (18)F-FDG to the staff outside the patient room. Conversely, despite the low administered activity of (89)Zr, it gives rise to a comparable or even lower dose than (18)F-FDG to the staff near the patient. This interesting result raises apparently contradictory implications in the radiation protection considerations of a PET/CT facility. ADVANCES IN KNOWLEDGE: To the best of our knowledge, radiation exposure to staff and public in the PET/CT unit using (89)Zr has not been investigated. The ultimate output of this study will lead to the optimal design of the facility for routine use of (89)Zr.
Authors: Pontus K E Börjesson; Yvonne W S Jauw; Remco de Bree; Jan C Roos; Jonas A Castelijns; C René Leemans; Guus A M S van Dongen; Ronald Boellaard Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Iris Verel; Gerard W M Visser; Ronald Boellaard; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen Journal: J Nucl Med Date: 2003-08 Impact factor: 10.057